We are live on ! Find out more
Calamos Advisors

Calamos Advisors Portfolio holdings

AUM $28.2B
1-Year Est. Return 21.78%
This Fund
S&P 500
This Quarter Est. Return
+0.71%
1 Year Est. Return
+21.78%
3 Year Est. Return
+69.57%
5 Year Est. Return
+92%
10 Year Est. Return
+282.63%
AUM
$22.9B
AUM Growth
+$1.01B
Cap. Flow
-$5.41B
Cap. Flow %
-23.63%
Top 10 Hldgs %
20.65%
Holding
1,090
New
128
Increased
343
Reduced
93
Closed
104

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$41.8M
2
AAPL icon
Apple
AAPL
+$35.4M
3
AMZN icon
Amazon
AMZN
+$34.6M
4
AESC
The AES Corporation
AESC
+$30.3M
5
ADBE icon
Adobe
ADBE
+$25.6M

Sector Composition

Rank Sector Weight
1 Technology 15.1%
2 Financials 8.11%
3 Healthcare 7.32%
4 Consumer Discretionary 6.91%
5 Communication Services 6.44%

Similar funds

Calamos Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Calamos Advisors held 1,090 positions worth $22.9B, up 4.6% from $21.9B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Calamos Advisors withdrew a net $5.41B in Q3 2021, closing 104 positions and reducing 93 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Calamos Advisors opened a new position in AstraZeneca worth $17.8M.

  • Calamos Advisors's largest Q3 2021 buy was AstraZeneca: 148,454 shares worth $17.8M.
  • Calamos Advisors added most to Microsoft in Q3 2021, an estimated $41.8M increase.
  • Calamos Advisors's biggest Q3 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $236M.
  • Calamos Advisors fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $31.2M.
  • Calamos Advisors's ten largest holdings make up 21% of its $22.9B portfolio in Q3 2021.
  • Calamos Advisors opened 128 new positions and closed 104 in Q3 2021.
  • Calamos Advisors's portfolio value rose 4.6% quarter-over-quarter to $22.9B.

Based on Calamos Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.